Neoadjuvant mFOLFOXIRI plus bevacizumab reduces peritoneal tumor burden in colorectal cancer patients.
Chemo before surgery may reduce tumor burden in colorectal cancer patients
This phase II randomized controlled trial evaluated 53 patients with resectable peritoneal metastasis of colorectal cancer. Neoadjuvant mFOL…
A trial suggests chemo before surgery might lower tumor markers for colorectal cancer patients with spread to the abdomen.
Two-Case Report Evaluates Lisaftoclax Plus Ixazomib and Dexamethasone in Relapsed Multiple Myeloma
Report reveals disease control in two high-risk myeloma patients
This publication is a case report involving 2 patients with transplant-ineligible relapsed or refractory ultra-high-risk multiple myeloma. I…
Two patients with ultra-high-risk myeloma achieved durable disease control using a new drug combination after CAR-T therapy.
Narrative review on precision prevention for women with inherited gynecologic cancer susceptibility
New Plan Cuts Cancer Risk for High-Risk Women
This narrative review addresses ovarian, endometrial, and fallopian tube cancer in women with inherited gynecologic cancer susceptibility. T…
Women with strong family histories of ovarian or uterine cancer can now take smarter, personalized steps to reduce their risk — and it’s cha…
Randomized Phase II Trial Evaluates Ociperlimab Plus Tislelizumab and BAT1706 in Advanced Hepatocellular Carcinoma
Adding a new drug did not help liver cancer patients survive longer
This randomized phase II trial enrolled 94 patients with advanced hepatocellular carcinoma. The objective response rate was 37.1% for ociper…
A new drug combination showed promise for advanced liver cancer, but adding a third drug did not improve results.
Zanubrutinib associated with higher 3-year PFS versus acalabrutinib-venetoclax in treatment-naive CLL
Zanubrutinib outperforms combo therapy for early leukemia
This post hoc indirect comparison analyzed treatment-naive chronic lymphocytic leukemia patients without del(17p) from phase 3 RCTs. Zanubru…
A single pill for early leukemia may work better than taking multiple drugs, offering a simpler and more effective option for patients who w…
Camrelizumab Associated With Higher Progression Risk Versus Pembrolizumab in Nonsquamous NSCLC Cohort
Sintilimab May Be Safer Lung Cancer Treatment
This retrospective cohort study evaluated 409 patients with stage IIIB-IV non-small cell lung cancer receiving PD-1 inhibitors. In nonsquamo…
One lung cancer drug may cause fewer serious side effects than others while working just as well, a real-world study suggests.
Narrative review finds BRCA testing increased 7%-47% but gaps remain in breast cancer
Breast Cancer Gene Testing Grows, But Gaps Remain for Some Patients
This targeted literature review of 35 publications (32 studies) examines germline BRCA testing patterns in US breast cancer patients. It fin…
A review of 35 studies shows BRCA testing rates rose 7% to 47% over time, yet eligible patients with hormone-positive early breast cancer st…
Case report reviews capmatinib off-label use in two patients with radiation-induced MET-fusion glioma
Capmatinib Shows Promise Against Rare Brain Tumors
This case report with literature review describes off-label capmatinib use in two patients with radiation-induced gliomas harboring MET fusi…
A drug used for lung cancer is now helping some children with rare, deadly brain tumors live longer, even when standard treatments fail.
Machine learning model predicted FOLFIRINOX dose modifications in pancreatic ductal adenocarcinoma cohort
Most patients on strong pancreatic cancer chemo needed a dose change
This cohort study included 514 patients with pancreatic ductal adenocarcinoma treated at UCSF oncology clinics. XGBoost models showed AUCs r…
Over 60% of patients with pancreatic cancer needed a dose adjustment during treatment with FOLFIRINOX at UCSF clinics.
Retrospective analysis finds sarcopenia associated with shorter disease-free survival in pancreatic neuroendocrine tumor patients
Low muscle mass linked to shorter disease-free survival in pancreatic tumor patients
This retrospective cohort study included 86 patients who underwent curative-intent resection for pancreatic neuroendocrine tumors. Univariab…
Low muscle mass before surgery was linked to shorter disease-free survival in patients with pancreatic neuroendocrine tumors, though this li…
Review Examines Artificial Intelligence Guided Acupuncture Decision Making and Treatment
AI Helps Doctors Choose Acupuncture Points With More Accuracy
This review explores the integration of artificial intelligence into acupuncture decision making and treatment protocols. The authors discus…
Smart machines now help doctors choose acupuncture points more accurately while monitoring safety during treatment sessions for better patie…
Mini review discusses translational hurdles and classification limitations in tumor-host interface research.
New review highlights hurdles in treating complex tumors.
This mini review addresses the limitations of traditional pathological classification and the translational hurdles of TME-directed therapie…
A fresh look at tumor treatment reveals big challenges in understanding how cancer cells interact with their environment and why current met…